CERVOMED INC (CRVO) Stock Fundamental Analysis

NASDAQ:CRVO • US15713L1098

3.99 USD
-0.41 (-9.32%)
Last: Feb 27, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CRVO. CRVO was compared to 521 industry peers in the Biotechnology industry. CRVO has a great financial health rating, but its profitability evaluates not so good. CRVO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • CRVO had negative earnings in the past year.
  • CRVO had a negative operating cash flow in the past year.
  • In the past 5 years CRVO always reported negative net income.
  • CRVO had a negative operating cash flow in each of the past 5 years.
CRVO Yearly Net Income VS EBIT VS OCF VS FCFCRVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • CRVO has a worse Return On Assets (-83.58%) than 69.10% of its industry peers.
  • CRVO's Return On Equity of -98.36% is in line compared to the rest of the industry. CRVO outperforms 45.68% of its industry peers.
Industry RankSector Rank
ROA -83.58%
ROE -98.36%
ROIC N/A
ROA(3y)-42.82%
ROA(5y)-50.07%
ROE(3y)-49.37%
ROE(5y)-56.44%
ROIC(3y)N/A
ROIC(5y)N/A
CRVO Yearly ROA, ROE, ROICCRVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • CRVO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRVO Yearly Profit, Operating, Gross MarginsCRVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • CRVO has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CRVO has been increased compared to 5 years ago.
  • There is no outstanding debt for CRVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRVO Yearly Shares OutstandingCRVO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
CRVO Yearly Total Debt VS Total AssetsCRVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • CRVO has an Altman-Z score of -0.50. This is a bad value and indicates that CRVO is not financially healthy and even has some risk of bankruptcy.
  • CRVO has a Altman-Z score (-0.50) which is in line with its industry peers.
  • CRVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.5
ROIC/WACCN/A
WACCN/A
CRVO Yearly LT Debt VS Equity VS FCFCRVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

  • CRVO has a Current Ratio of 6.66. This indicates that CRVO is financially healthy and has no problem in meeting its short term obligations.
  • CRVO's Current ratio of 6.66 is fine compared to the rest of the industry. CRVO outperforms 67.56% of its industry peers.
  • A Quick Ratio of 6.66 indicates that CRVO has no problem at all paying its short term obligations.
  • The Quick ratio of CRVO (6.66) is better than 68.14% of its industry peers.
Industry RankSector Rank
Current Ratio 6.66
Quick Ratio 6.66
CRVO Yearly Current Assets VS Current LiabilitesCRVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for CRVO have decreased strongly by -80.12% in the last year.
  • CRVO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -38.81%.
EPS 1Y (TTM)-80.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.73%
Revenue 1Y (TTM)-38.81%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-83.37%

3.2 Future

  • CRVO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.47% yearly.
  • The Revenue is expected to grow by 43.66% on average over the next years. This is a very strong growth
EPS Next Y-34.74%
EPS Next 2Y2.4%
EPS Next 3Y8.48%
EPS Next 5Y10.47%
Revenue Next Year-47.93%
Revenue Next 2Y-69.28%
Revenue Next 3Y-25.99%
Revenue Next 5Y43.66%

3.3 Evolution

CRVO Yearly Revenue VS EstimatesCRVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
CRVO Yearly EPS VS EstimatesCRVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -500 -1K -1.5K

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • CRVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRVO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRVO Price Earnings VS Forward Price EarningsCRVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRVO Per share dataCRVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.4%
EPS Next 3Y8.48%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CRVO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CERVOMED INC

NASDAQ:CRVO (2/27/2026, 8:00:00 PM)

3.99

-0.41 (-9.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)03-16
Inst Owners23.45%
Inst Owner Change5.18%
Ins Owners24.03%
Ins Owner Change2.01%
Market Cap36.91M
Revenue(TTM)6.16M
Net Income(TTM)-25.58M
Analysts81.43
Price Target22.88 (473.43%)
Short Float %3.74%
Short Ratio3.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.8%
Min EPS beat(2)-8.93%
Max EPS beat(2)-6.67%
EPS beat(4)1
Avg EPS beat(4)-5.85%
Min EPS beat(4)-24.49%
Max EPS beat(4)16.71%
EPS beat(8)2
Avg EPS beat(8)-9.02%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-39.13%
Min Revenue beat(2)-77.68%
Max Revenue beat(2)-0.58%
Revenue beat(4)2
Avg Revenue beat(4)-11.94%
Min Revenue beat(4)-77.68%
Max Revenue beat(4)21.32%
Revenue beat(8)5
Avg Revenue beat(8)6.67%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-25.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-22.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.99
P/FCF N/A
P/OCF N/A
P/B 1.42
P/tB 1.42
EV/EBITDA N/A
EPS(TTM)-2.9
EYN/A
EPS(NY)-1.93
Fwd EYN/A
FCF(TTM)-2.69
FCFYN/A
OCF(TTM)-2.69
OCFYN/A
SpS0.67
BVpS2.81
TBVpS2.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -83.58%
ROE -98.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.82%
ROA(5y)-50.07%
ROE(3y)-49.37%
ROE(5y)-56.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.66
Quick Ratio 6.66
Altman-Z -0.5
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-80.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.73%
EPS Next Y-34.74%
EPS Next 2Y2.4%
EPS Next 3Y8.48%
EPS Next 5Y10.47%
Revenue 1Y (TTM)-38.81%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-83.37%
Revenue Next Year-47.93%
Revenue Next 2Y-69.28%
Revenue Next 3Y-25.99%
Revenue Next 5Y43.66%
EBIT growth 1Y-114.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-67.9%
EBIT Next 3Y-64.22%
EBIT Next 5Y-24.41%
FCF growth 1Y-197.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-197.44%
OCF growth 3YN/A
OCF growth 5YN/A

CERVOMED INC / CRVO FAQ

What is the fundamental rating for CRVO stock?

ChartMill assigns a fundamental rating of 3 / 10 to CRVO.


Can you provide the valuation status for CERVOMED INC?

ChartMill assigns a valuation rating of 0 / 10 to CERVOMED INC (CRVO). This can be considered as Overvalued.


What is the profitability of CRVO stock?

CERVOMED INC (CRVO) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for CRVO stock?

The Earnings per Share (EPS) of CERVOMED INC (CRVO) is expected to decline by -34.74% in the next year.